A new tablet for breakthrough cancer pain is now available in the United States for patients tolerant to opioid therapy.
The Biopharmaceutical company Galena Biopharma has launched Abstral (fentanyl) sublingual tablets, intended for breakthrough pain management in cancer patients 18 and older who are already receiving, and who are tolerant to, opioid therapy for cancer-related pain.
New treatment a 'tremendous milestone'
The company bought Abstral last March and completely overhauled the drug and its production, as well as implementing a patient assistance program.
Said Mark J. Ahn, president and chief executive officer of Galena:
As an oncology company dedicated to improving patients' lives, we are thrilled to introduce Abstral as our first commercial product and offer cancer patients relief from their breakthrough pain. We believe Abstral delivers best in class performance because it is simple to carry, simple to use, and requires no speacial handling or disposal. We have a commercial team of highly dedicated, patient-focused professionals with experience in both pain and oncology who have helped us reach this tremendous milestone for Galena. I look forward to reporting our continued progress later this year.
Breakthrough cancer pain occurs in many patients already being given long-acting opioid therapy. It is defined as a transient exacerbation of pain that occurs either spontaneously or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain.
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.